Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Clin Cancer Res. 2018 Apr 24;24(15):3632–3643. doi: 10.1158/1078-0432.CCR-18-0041

Figure 4. GDC-0919 enhances radiation response in glioblastoma.

Figure 4.

TRP tumors were grown (A) subcutaneously (SC) or (B) & (C) intracranially (IC) in immune competent C57BL/6 mice. MRI was obtained to confirm the establishment of IC tumors prior to the initiation of therapy. Following establishment of tumors, mice were randomized to treatment as described in schema. GDC-0919 was given orally at a concentration of 200 mg/kg twice a day (six days a week) for 2–3 weeks. Each treatment arm consisted of a minimum of 6 mice. ** = p<0.005.